Bend Research has added a new cGMP spray-drying facility, expanding its capabilities and expertise for the development and manufacture of high-potency drug candidates.
 
The new facility accommodates the manufacture of a range of compound types and safety classifications, ranging from inhalable biotherapeutics to oral solid high-potency small molecules. The facility is separated from the company’s other development and cGMP manufacturing facilities, and is designed for high containment operations with the highest safety and quality standards.
 
“We’re excited to offer our clients expanded cGMP spray-drying capability for high-potency compounds,” said Rod Ray, chief executive officer. “This facility will complement our small molecule cGMP spray-drying capabilities.”